Amygdala activity after subchronic escitalopram administration in healthy volunteers: A pharmaco-functional magnetic resonance imaging study. Lukow, P. B, Lowther, M., Pike, A. C, Yamamori, Y., Chavanne, A. V, Gormley, S., Aylward, J., McCloud, T., Goble, T., Rodriguez-Sanchez, J., Tuominen, E. W, Buehler, S. K, Kirk, P., & Robinson, O. J Journal of Psychopharmacology, 38(12):1071–1082, December, 2024.
Amygdala activity after subchronic escitalopram administration in healthy volunteers: A pharmaco-functional magnetic resonance imaging study [link]Paper  doi  abstract   bibtex   
Background: Selective serotonin reuptake inhibitors (SSRIs) are used for the treatment of several conditions including anxiety disorders, but the basic neurobiology of serotonin function remains unclear. The amygdala and prefrontal cortex are strongly innervated by serotonergic projections and have been suggested to play an important role in anxiety expression. However, serotonergic function in behaviour and SSRI-mediated neurobiological changes remain incompletely understood. Aims: To investigate the neural correlates of subchronic antidepressant administration. Methods: We investigated whether the 2- to 3-week administration of a highly selective SSRI (escitalopram) would alter brain activation on a task robustly shown to recruit the bilateral amygdala and frontal cortices in a large healthy volunteer sample. Participants performed the task during a functional magnetic resonance imaging acquisition before ( n = 96) and after subchronic escitalopram ( n = 46, days of administration mean (SD) = 15.7 (2.70)) or placebo ( n = 40 days of administration mean (SD) = 16.2 (2.90)) self-administration. Results: Compared to placebo, we found an elevation in right amygdala activation to the task after escitalopram administration without significant changes in mood. This effect was not seen in the left amygdala, the dorsomedial region of interest, the subgenual anterior cingulate cortex or the right fusiform area. There were no significant changes in connectivity between the dorsomedial cortex and amygdala or the subgenual anterior cingulate cortex after escitalopram administration. Conclusions: To date, this most highly powered study of subchronic SSRI administration indicates that, contrary to effects often seen in patients with anxiety disorders, subchronic SSRI treatment may increase amygdala activation in healthy controls. This finding highlights important gaps in our understanding of the functional role of serotonin.
@article{lukow_amygdala_2024,
	title = {Amygdala activity after subchronic escitalopram administration in healthy volunteers: {A} pharmaco-functional magnetic resonance imaging study},
	volume = {38},
	issn = {0269-8811, 1461-7285},
	shorttitle = {Amygdala activity after subchronic escitalopram administration in healthy volunteers},
	url = {https://journals.sagepub.com/doi/10.1177/02698811241286773},
	doi = {10.1177/02698811241286773},
	abstract = {Background:
              Selective serotonin reuptake inhibitors (SSRIs) are used for the treatment of several conditions including anxiety disorders, but the basic neurobiology of serotonin function remains unclear. The amygdala and prefrontal cortex are strongly innervated by serotonergic projections and have been suggested to play an important role in anxiety expression. However, serotonergic function in behaviour and SSRI-mediated neurobiological changes remain incompletely understood.
            
            
              Aims:
              To investigate the neural correlates of subchronic antidepressant administration.
            
            
              Methods:
              We investigated whether the 2- to 3-week administration of a highly selective SSRI (escitalopram) would alter brain activation on a task robustly shown to recruit the bilateral amygdala and frontal cortices in a large healthy volunteer sample. Participants performed the task during a functional magnetic resonance imaging acquisition before ( n = 96) and after subchronic escitalopram ( n = 46, days of administration mean (SD) = 15.7 (2.70)) or placebo ( n = 40 days of administration mean (SD) = 16.2 (2.90)) self-administration.
            
            
              Results:
              Compared to placebo, we found an elevation in right amygdala activation to the task after escitalopram administration without significant changes in mood. This effect was not seen in the left amygdala, the dorsomedial region of interest, the subgenual anterior cingulate cortex or the right fusiform area. There were no significant changes in connectivity between the dorsomedial cortex and amygdala or the subgenual anterior cingulate cortex after escitalopram administration.
            
            
              Conclusions:
              To date, this most highly powered study of subchronic SSRI administration indicates that, contrary to effects often seen in patients with anxiety disorders, subchronic SSRI treatment may increase amygdala activation in healthy controls. This finding highlights important gaps in our understanding of the functional role of serotonin.},
	language = {en},
	number = {12},
	urldate = {2024-11-06},
	journal = {Journal of Psychopharmacology},
	author = {Lukow, Paulina B and Lowther, Millie and Pike, Alexandra C and Yamamori, Yumeya and Chavanne, Alice V and Gormley, Siobhan and Aylward, Jessica and McCloud, Tayla and Goble, Talya and Rodriguez-Sanchez, Julia and Tuominen, Ella W and Buehler, Sarah K and Kirk, Peter and Robinson, Oliver J},
	month = dec,
	year = {2024},
	pages = {1071--1082},
}
Downloads: 0
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021